|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
2.
|
Canadian Cancer Society/National Cancer
Institute of Canada: Canadian Cancer Statistics 2008. Toronto: ISSN
0835-2976. 2008
|
|
3.
|
Reske SN: PET and PET-CT of malignant
tumors of the exocrine pancreas. Radiologe. 49:131–136. 2009.(In
German).
|
|
4.
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
American Cancer Society: Cancer Facts and
Figures 2007 [M]. American Cancer Society; New York, NY: pp. 51–52.
2007
|
|
6.
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
7.
|
O’Reilly EM and Abou-Alfa GK: Cytotoxic
therapy for advanced pancreatic adenocarcinoma. Semin Oncol.
34:347–353. 2007.
|
|
8.
|
O’Reilly EM: Pancreatic adenocarcinoma:
new strategies for success. Gastrointest Cancer Res. 3:S11–S15.
2009.PubMed/NCBI
|
|
9.
|
Tingstedt B, Johansson P, Andersson B and
Andersson R: Predictive factors in pancreatic ductal
adenocarcinoma: role of the inflammatory response. Scand J
Gastroenterol. 42:754–759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kang SP and Saif MW: Optimal second-line
treatment options for gemcitabine refractory advanced pancreatic
cancer patients. Can we establish standard of care with available
data? J Oral Pathol. 9:83–90. 2008.
|
|
11.
|
Kunnumakkara AB, Guha S, Krishnan S, et
al: Curcumin potentiates antitumor activity of gemcitabine in an
orthotopic model of pancreatic cancer through suppression of
proliferation, angiogenesis, and inhibition of nuclear
factor-kappaB-regulated gene products. Cancer Res. 67:3853–3861.
2007. View Article : Google Scholar
|
|
12.
|
Harikumar KB, Kunnumakkara AB, Sethi G,
Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S
and Aggarwal BB: Resveratrol, a multitargeted agent, can enhance
antitumor activity of gemcitabine in vitro and in orthotopic mouse
model of human pancreatic cancer. Int J Cancer. 127:257–268.
2010.PubMed/NCBI
|
|
13.
|
Banerjee S, Kaseb AO, Wang Z, Kong D,
Mohammad M, Padhye S, Sarkar FH and Mohammad RM: Antitumor activity
of gemcitabine and oxaliplatin is augmented by thymoquinone in
pancreatic cancer. Cancer Res. 69:5575–5583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang ZH, Chen H, Guo HC, Tong HF, Liu JX,
Wei WT, Tan W, Ni ZL, Liu HB and Lin SZ: Enhanced antitumor
efficacy by the combination of emodin and gemcitabine against human
pancreatic cancer cells via downregulation of the expression of
XIAP in vitro and in vivo. Int J Oncol. 39:1123–1131.
2011.PubMed/NCBI
|
|
15.
|
Chen H, Wei W, Guo Y, Liu A, Tong H, Wang
Z, Tan W, Liu J and Lin S: Enhanced effect of gemcitabine by emodin
against pancreatic cancer in vivo via cytochrome C-regulated
apoptosis. Oncol Rep. 25:1253–1261. 2011.PubMed/NCBI
|
|
16.
|
Wei WI, Chen H, Ni ZL, Liu HI, Tong HF,
Fan L, Liu A, Qiu MU, Liu DL, Guo HC, Wang ZH and Lin SZ: Antitumor
and apoptosis-promoting properties of emodin, an anthraquinone
derivative from Rheum officinale Baill, against pancreatic
cancer in mice via inhibition of Akt activation. Int J Oncol.
39:1381–1390. 2011.PubMed/NCBI
|
|
17.
|
Sun HD, Huang SX and Han QB: Diterpenoids
from isodon species and their biological activities. Nat Prod Rep.
23:673–698. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Huang J, Wu L, Tashiro S, Onodera S and
Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2
apoptosis through p53, MAPK, and mitochondrial signaling pathways.
J Pharmacol Sci. 107:370–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Jin S, Shen JN, Wang J, Huang G and Zhou
JG: Oridonin induced apoptosis through AKT and MAPKS signaling
pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S
and Ikejima T: Fas/FasL signaling allows extracelluar-signal
regulated kinase to regulate cytochrome c release in
oridonin-induced apoptotic U937 cells. Biol Pharm Bull.
29:1873–1879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Li D, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Oridonin induced A431 cell apoptosis partially through
blockage of the RAS/RAF/ERK signal pathway. J Pharmacol Sci.
103:56–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ikezoe T, Chen SS, Tong XJ, Heber D,
Taguchi H and Koeffler HP: Oridonin induces growth inhibition and
apoptosis of a variety of human cancer cells. Int J Oncol.
23:1187–1193. 2003.PubMed/NCBI
|
|
23.
|
Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM,
Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via
PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta
Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Hsieh TC, Wijeratne EK, Liang JY,
Gunatilaka AL and Wu JM: Differential control of growth, cell cycle
progression, and expression of NF-kappaB in human breast cancer
cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin,
diterpenoids from the chinese herb Rabdosia rubescens.
Biochem Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera
S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via
activating ERK-p53 apoptotic pathway and inhibiting PTK-RAS-RAFJNK
survival pathway in murine fibrosarcoma L929 cells. Arch Biochem
Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo
ZY, Xu MH, Wang ST, Jiang B, Liu F, Zhao YZ, Fang Y, Chen FY and Wu
YL: Oridonin induces apoptosis and senescence in colorectal cancer
cells by increasing histone hyperacetylation and regulation of p16,
p21, p27 and c-myc. BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Rufini A and Melino G: Cell death
pathology: The war against cancer. Biochem Biophys Res Commun.
414:445–450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Martelli AM, Nyåkern M, Tabellini G,
Bortul R, Tazzari PL, Evangelisti C and Cocco L: Phosphoinositide
3-kinase/Akt signaling pathway and its therapeutical implications
for human acute myeloid leukemia. Leukemia. 20:911–928. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Wu GS: The functional interactions between
the p53 and MAPK signaling pathways. Cancer Biol Ther. 3:156–161.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
McCubrey JA, Lahair MM and Franklin RA:
Reactive oxygen species-induced activation of the MAP kinase
signaling pathways. Antioxid Redox Signal. 8:1775–1789. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Kholodenko BN and Birtwistle MR:
Four-dimensional dynamics of MAPK information processing systems.
Wiley Interdiscip Rev Syst Biol Med. 1:28–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Rodríguez-Berriguete G, Fraile B,
Martínez-Onsurbe P, Olmedilla G, Paniagua R and Royuela M: MAP
kinases and prostate cancer. J Signal Transduct.
2012:1691702012.PubMed/NCBI
|
|
34.
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Harris SL and Levine AJ: The p53 pathway:
positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Shi Y, Sahu RP and Srivastava SK: Triphala
inhibits both in vitro and in vivo xenograft growth of pancreatic
tumor cells by inducing apoptosis. BMC Cancer. 8:2942008.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Ma Y, Yu WD, Kong RX, Trump DL and Johnson
CS: Role of nongenomic activation of phosphatidylinositol
3-kinase/Akt and mitogen-activated protein kinase/extracellular
signal regulated kinase kinase/extracellular signal-regulated
kinase 1/2 pathway in 1,25D3-mediated apoptosis in squamous cell
carcinoma cells. Cancer Res. 66:8131–8138. 2006.
|
|
38.
|
Filomeni G, Graziani I, Rotilio G and
Ciriolo MR: trans-Resveratrol induces apoptosis in human breast
cancer cells MCF-7 by the activation of MAP kinases pathways. Genes
Nutr. 2:295–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Bulavin DV and Fornace AJ Jr: p38 MAP
kinase’s emerging role as a tumor suppressor. Adv Cancer Res.
92:95–118. 2004.
|
|
40.
|
Vousden KH and Prives C: P53 and
prognosis: new insights and further complexity. Cell. 120:7–10.
2005.PubMed/NCBI
|
|
41.
|
Galluzzi L, Morselli E, Kepp O, Tajeddine
N and Kroemer G: Targeting p53 to mitochondria for cancer therapy.
Cell Cycle. 7:1949–1955. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Califice S, Waltregny D, Castronovo V and
van den Brûle F: Prostate carcinoma cell lines and apoptosis: a
review. Rev Med Liege. 59:704–710. 2004.(In French).
|
|
43.
|
Kim YS, Lee HJ, Jang C, Kim HS and Cho YJ:
Knockdown of RCAN1.4 increases susceptibility to FAS-mediated and
DNA damage-induced apoptosis by upregulation of p53 expression.
Korean J Physiol Pharmacol. 13:483–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
